Inflammatory bowel diseases, also known by their acronym IBD, mainly include two pathologies: Crohn’s disease and ulcerative colitis (UC).
The incidence of these diseases, which are expressed by outbreaks interspersed with phases of pause or remission, is only increasing. In France, it is estimated that there are approximately 270,000 people affected by IBD. The number of new cases of Crohn’s disease or UC each year is between 4 and 5 per 100,000 inhabitants.
While these numbers are steadily rising, there is no cure today. However, if we are not yet able to recover from inflammatory bowel disease, it is still possible to control the disease. Research focuses every day on the mechanisms of these pathologies in order to better understand them and to develop therapies.
Genetics, the role of immunity, the importance of intestinal flora and environmental factors including the role of diet are studied by scientific teams.
Treatments are increasingly administered at home, and the management of these pathologies is becoming multidisciplinary. Taking care of IBD requires a holistic approach, taking into account the medicinal aspect as well as the lifestyle and dietary rules, or even the management of the stress of patients who suffer from it.
Celltrion Healthcare is a biopharmaceutical company. It was founded in 2002 in South Korea, and the French subsidiary was created in 2019. Specialized in the development of innovative molecules and biosimilar products, it markets treatments used in the management of chronic inflammatory diseases of the intestine.
In order to offer treatments that best fit into patients’ daily lives, Celltrion Healthcare works with experts, nurses and patient associations.
Celltrion Healthcare also contributes to the evolution of IBD care by supporting academic research and training. The company supports learned societies and the community of gastroenterologists by participating in national and international congresses in the field.
Content designed and proposed by L’Agence Delta. The editorial staff of Le Figaro did not participate in the production of this article.
